EFEnrico Felici

Enrico Felici

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Enrico Felici has a total of 307 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiovascular Risk Assessment in Childhood: Focus on Family History and Lifestyle Habits in the Real-World, Cross-Sectional, Community-Based RISCAPED Study

    by Silvia Alessandra Magrassi, Enrica Bertelli, Costanza Massarino, Enrico Felici, Andrea Secco, Barbara Roviglione, Riccardo Mazzucco, Marinella Bertolotti, Maria Carla Giaccari, Annalisa Roveta, et al.

    Background and Objectives: Pediatric cardiovascular risk factors tend to track into adulthood, accelerating the atherosclerotic process. This study aimed to assess the prevalence of cardiometabolic risk factors, integrating anthropometric parameters, central adiposity indices, early growth trajectories, family history, and household lifestyle, in a primary-care pediatric cohort (the RISCAPED study). Materials and Methods: A cross-sectional multicenter study was conducted across primary care pediatric practices in the province of Alessandria, Northwest Italy, enrolling children aged 6 to 12 years. Weight status was classified according to World Health Organization 2007 criteria, abdominal adiposity by Waist-to-Height Ratio (WHtR > 0.5), and high blood pressure according to American Academy of Pediatrics percentiles (≥95th percentile). Family lifestyle habits were evaluated via the Family Nutrition and Physical Activity (FNPA) screening tool. Factors independently associated with high blood pressure and excess weight were identified using multivariable logistic regression models. Results: Among 479 children with complete anthropometric data (median age: 9.0 years), 42.3% presented with excess weight (21.9% overweight, 20.4% obesity). WHtR increased significantly across weight groups (median 0.44, 0.46 and 0.50, respectively; p < 0.001). Previously undiagnosed high blood pressurewas identified in 7.1% of the cohort, with a significant systolic blood pressure gradient (p < 0.001). Rapid weight gain during early infancy was significantly more frequent in children with obesity (10.6% vs. p = 0.025). In multivariable models, a family history of thrombophilic disorders (OR 3.16, 95% CI 1.27–7.41) and a less favourable FNPA score (OR 0.94 per point, 0.89–0.99) were independently associated with high blood pressure; a family history of hyperglycemia was associated overweight/obesity (OR 1.71, 1.06–2.78), and a family history of obesity wa associated with childhood obesity (OR 1.71, 1.02–2.88). Conclusions: Cardiovascular risk factors emerge early during primary school age, with central adiposity and silent high blood pressure manifesting prior to clinical disease. Multi-generational family history emerged as a consistent marker of risk, supporting routine multi-domain cardiovascular screening in primary pediatric healthcare.

  • Open Access

    Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025)

    by Paolo Manzoni, Matteo Riccò, Chryssoula Tzialla, Graziano Barera, Paolo Del Barba, Simona De Franco, Guido Pellegrini, Enrico Crapanzano, Giangiacomo Nicolini, Andrea Alba, et al.

    Nirsevimab is a long-acting monoclonal antibody designed to prevent infections due to respiratory syncytial virus (RSV). Here we report on a retrospective, multicenter study encompassing a total of 19 Italian neonatal and pediatric centers evaluating the epidemiology of lower respiratory tract infection (LRTI)-related hospitalizations in infants younger than 2 years during the first RSV season following the introduction of nirsevimab prophylaxis. A total of 401 hospitalizations were reported, with 40.4% being in children with previous prophylaxis with nirsevimab. Respiratory syncytial virus was the most frequently identified pathogen (47.5%), followed by rhinovirus/enterovirus (20.2%) and human metapneumovirus (hMPV; 6.9%). In multivariable analyses adjusted for age, sex, and month of diagnosis, prior nirsevimab immunization was associated with a significantly reduced likelihood of RSV-related hospitalization (adjusted odds ratio [aOR], 0.259; 95% CI, 0.157–0.427), corresponding to an estimated effectiveness of 74.1% (95% CI, 57.3–84.3). Conversely, nirsevimab-immunized infants showed increased odds of hospitalization due to hMPV (aOR, 2.490; 95% CI, 1.019–6.085) and rhinovirus/enterovirus (aOR, 2.573; 95% CI, 1.424–4.650). Lower respiratory tract infections associated with hMPV predominantly occurred outside the typical RSV season, being associated with moderate-to-severe clinical presentations. These findings confirm the real-world effectiveness of nirsevimab against RSV hospitalizations, also highlighting the need for the continued surveillance of non-RSV respiratory pathogens in the context of universal RSV immunoprophylaxis.


  • Open Access

    Body Mass Index Status in Italian Children with Celiac Disease at Diagnosis and After 12–18 Months on a Gluten-Free Diet: A Multicenter Retrospective Study

    by Alice Monzani, Elena Pozzi, Luisa Abbattista, Marco Crocco, Federica Malerba, Silvia Marcolin, Noemi Paggi, Monica Montuori, Giulia Gagliostro, Claudia Mandato, et al.

    Background/Objectives: The distribution of body mass index (BMI) categories at celiac disease (CD) diagnosis in children is changing, and the impact of a gluten-free diet (GFD) on BMI status remains incompletely understood. We aimed to evaluate the distribution of BMI categories at CD diagnosis and their changes after 12–18 months on a GFD in Italian children. Methods: Children and adolescents aged 0–18 years who received a new diagnosis of CD at 23 Pediatric Gastroenterology referral centers in Italy were retrospectively enrolled. We analyzed their BMI status at diagnosis, classifying them as underweight, normal weight, overweight, or obese. BMI changes were assessed after 12–18 months on a GFD. Results: Among the 4967 children (mean age 7.1 ± 4.1 years, M:F = 1827:3140), 4.4% were underweight, 77.5% normal weight, 12.7% overweight, and 5.4% obese at diagnosis. Overweight/obese children were more likely to have a family history of CD, associated conditions, and an asymptomatic presentation. After 12–18 months of GFD, 55.7% of underweight children achieved normal weight, and 23% of overweight/obese reverted to normal weight. Conversely, 10.9% of normal-weight children and 3.2% of underweight children became overweight/obese. Conclusions: At diagnosis, most children were normal weight, but 18.1% presented with overweight/obesity. After 12–18 months on a GFD, BMI normalized in over half of underweight but in fewer than one-quarter of overweight/obese subjects.


  • Open Access

    Gut Microbiota Profiling by 16S rRNA Sequencing in Children with Mild or Intermittent Asthma: A Pilot Study in Alessandria, Italy

    by Valentina Pizzo, Alessia Francese, Paolo Bottino, Carlotta Bertolina, Franca Gotta, Michela Gandino, Enrico Felici, Riccardo Mazzucco, Marinella Bertolotti, Annalisa Roveta, et al.

    Asthma is one of the most common chronic diseases in childhood, and the gut microbiota is increasingly recognized as a key player in its pathogenesis through the gut–lung axis. This pilot, cross-sectional study analyzed the intestinal microbiota of 20 children (6–9 years) with intermittent or mild persistent asthma, in the absence of a healthy control group. Stool samples were processed with 16S rRNA sequencing (Illumina iSeq100, V3–V6 regions) and analyzed with MicrobAT-SmartSeq software. Contrary to most literature, no enrichment of Proteobacteria was detected, and Faecalibacterium was not reduced but emerged as the most abundant genus. Higher adherence to the Mediterranean diet correlated with greater microbial richness, while asthma phenotypes showed no major taxonomic differences. Pharmacological treatments modulated microbial profiles: leukotriene antagonists correlated with protective taxa, whereas inhaled corticosteroids and bronchodilators were linked to reduced beneficial functions. These findings highlight an overall eubiotic microbiota in asthmatic schoolchildren and call for larger, controlled studies to confirm these novel observations.


  • Open Access

    Bifidobacterium adolescentis PRL2019 in Pediatric Irritable Bowel Syndrome: A Multicentric, Randomized, Double-Blind, Placebo-Controlled Trial

    by Valentina Giorgio, Giovanna Quatrale, Maurizio Mennini, Marisa Piccirillo, Silvia Furio, Giuseppe Stella, Alessandro Ferretti, Pasquale Parisi, Melania Evangelisti, Enrico Felici, et al.

    The gut microbiota plays a pivotal role in gastrointestinal inflammation and immune response since changes in microbiota may result in abnormal neurotransmitter expression, inducing changes in gastrointestinal sensory–motor function and leading to symptom onset in irritable bowel syndrome (IBS) patients. The Bifidobacterium adolescentis species has a documented immunomodulatory effect through its ability to produce γ-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the mammalian central nervous system, which is reduced in IBS patients. This is a multicentric, randomized, double-blind, placebo-controlled, parallel-arm trial aimed at evaluating the effectiveness of Bifidobacterium adolescentis PRL2019 in children with IBS. IBS children diagnosed according to Rome IV criteria were enrolled and randomized into two groups to receive one stick containing 20 × 109 colony-forming unit of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy) or an equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Clinical evaluation of symptoms was performed every four weeks using validated scores. Bowel habit characteristics were assessed using the Bristol Stool Chart (BSC). Seventy-two subjects (mean age 12.2 ± 1.8 years, 30 males) were enrolled and randomized into two groups, each of thirty-six patients. No significant differences were observed between the two groups regarding demographic characteristics, distribution of IBS subtypes, or baseline measures of IBS severity and BSC. The proportion of patients achieving complete remission was significantly higher in the BA Group (19/36; 52.8%) than in the Placebo Group (7/36; 19.4%, p = 0.003, odds ratio [OR] 0.216, 95% confidence interval [CI] 0.075–0.619). Both groups obtained a reduction in Total IBS Symptom Severity Scale (IBS SSS), Pain Intensity Score (PIS), Pain Frequency Score (PFS), and Life Interference Score (LIS) from T0 to T12. However, upon intergroup comparison, only in the BA group did the IBS-SSS (p = 0.001), PIS (p = 0.001), LIS (p = 0.015), and PFS (p = 0.005) significantly improve between T0 and T12. BSC showed a greater representation of normal stools (type 3–4) at the end of treatment in the BA group compared with baseline (25% vs. 58.3%, p = 0.004), especially in patients who presented an IBS–constipation subtype at T0 (44.5% vs. 19.4%, p = 0.02). In our study, Bifidobacterium adolescentis PRL2019 reduces the severity and frequency of symptoms in children with IBS, positively affecting bowel habits in children with the IBS–constipation subtype.


  • Open Access

    Early Surgical Resection in Pediatric Patients with Localized Ileo-Cecal Crohn’s Disease: Results of a Retrospective Multicenter Study

    by Isabella Madaffari, Edoardo Maria Muttillo, Alice La Franca, Fanny Massimi, Giorgio Castagnola, Alessandro Coppola, Silvia Furio, Marisa Piccirillo, Alessandro Ferretti, Maurizio Mennini, et al.

    Background: Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that also affects pediatric patients. It frequently presents as a localized disease, affecting the ileocecal area, ileum, or colon. It requires targeted therapy to achieve a good quality of life and long-term control of disease activity. Despite multiple medical therapies available, several patients benefit from surgical treatment. The aim of our study is to demonstrate how an early surgical approach can bring an improvement in disease activity, evaluating the Simple Endoscopic Score for Crohn’s Disease (SES-CD) and the Pediatric Crohn’s Disease Activity Index (PCDAI). Methods: A retrospective multicenter study was carried out from 2008 to 2023, including 29 patients, affected by localized CD. These data were analyzed: demographics, SES-CD, and PCDAI, before and after surgery. The differences between groups were analyzed using Student’s t-test for continuous variables, and Pearson’s Chi-squared test or Fisher’s exact test for categorical variables. Results: The SES-CD significantly decreased from 12 (median, range 1–15) to 0 (median, range 0–6) (p < 0.0001) and the PCDAI decreased from 30 (median, range 10–50) to 0 (median, range 0–15) (p < 0.0001). The rate of patients receiving enteral nutrition decreased from 51.7% preoperatively to 0% postoperatively (p = 0.0001). The rate of antibiotic use decreased from 13.8% to 0% (p = 0.0001). The rate of patients receiving ≥2 drugs decreased from 10.3% to 0% (p = 0.0001). Conclusions: The early surgical approach can be considered an excellent therapeutic strategy in patients with localized CD. Both parameters examined, SES-CD and PCDAI, demonstrated a clear improvement in the endoscopic images and in disease activity.


  • Open Access

    Lesson in understanding parents’ perspective: perception of quality of care and COVID-19-related fears among users of paediatric health services over the COVID-19 pandemic in 11 facilities in Italy

    by Paolo Dalena, Alessandro Zago, Angela Troisi, Gian Luca Trobia, Annunziata Lucarelli, Silvia Bressan, Silvia Fasoli, Stefano Martelossi, Riccardo Lubrano, Roberta Parrino, et al.

    Background: The COVID-19 pandemic had an important psychological impact on children and their families. This study aims to explore paediatric health services users’ perceptions of quality of care (QOC) and COVID-19-related fears, and their evolution over time in relation to COVID-19 pandemic.Methods: In a multicentre cross-sectional study involving 11 public hospitals providing paediatric care across the Italian territory, we collected data from services users through a validated questionnaire. We analysed four indicators—(1) QOC perceived in relation to COVID-19; (2) overall QOC perceived; (3) fear of accessing health services due to COVID-19; (4) fear of contracting COVID-19 in hospital—and calculated Spearman’s correlation indexes (ρ) with the number of COVID-19 new cases over time. Subgroup analyses were conducted by macroregions and single facility.Results: Data from 956 services users were analysed. QOC indicators were stable over time at values close to the maximum (range 77–100 and median 100 for COVID-19 QOC, range 74–98 and median 80 for overall QOC), and no correlations were found with the COVID-19 new cases (ρ=−0.073 and −0.016, respectively). Fear of accessing care and fear of contracting the infection varied over time in between 0%–52% and 0%–53%, respectively, but did not correlate directly with number of COVID-19 new cases (ρ=0.101, 0.107 and 0.233, 0.046, respectively). At subgroup analyses, significantly higher frequencies of fear (p values <0.05) and lower QOC (p values <0.001) were reported in South Italy, and three facilities showed moderate correlation between these indicators.Conclusions: COVID-19-related fears and perceived QOC may be mediated by more complex cultural and facility/regional-level factors, than simply by epidemic peaks. Subgroup analyses can help unpack major differences within the same country.


  • Open Access

    Evaluation of a Commercial Rapid Molecular Point-of-Care Assay for Differential Diagnosis Between SARS-CoV-2 and Flu A/B Infections in a Pediatric Setting

    by Paolo Bottino, Costanza Massarino, Christian Leli, Elisabetta Scomparin, Cristina Bara, Franca Gotta, Elisa Cornaglia, Enrico Felici, Michela Gentile, Sara Ranzan, et al.

    Given the ongoing COVID-19 pandemic, there is a need to identify SARS-CoV-2 and to differentiate it from other respiratory viral infections, especially influenza A and B, in various critical settings. Since their introduction, the use of rapid antigen tests has spread worldwide, but there is variability in their diagnostic accuracy. In the present study, we evaluated the clinical performance of the ID NOW™ COVID-19 2.0, a molecular point-of-care test (POCT) based on enzymatic isothermal amplification for the differential diagnosis of SARS-CoV-2 and influenza A/B in a pediatric emergency setting. A cohort of pediatric patients admitted between December 2022 and February 2023 were simultaneously tested with the POCT and standard laboratory molecular assay. Our findings showed high negative agreement of the POCT assay across the different age groups for SARS-CoV-2, influenza A, and influenza B (more than 98.0%), while its positive agreement varied significantly for the abovementioned viral species from 50.0% to 100%. These results highlight the potential of the ID NOW™ COVID-19 2.0 POCT assay as a reliable and rapid tool for excluding SARS-CoV-2 and influenza A/B infections in symptomatic pediatric patients, although its variable positive agreement suggests a need for confirmatory RT-qPCR testing in certain clinical and epidemiological settings in order to ensure accurate diagnosis and appropriate patient management.


  • Open Access

    Evaluation of the WHO standards to assess quality of care for children with acute respiratory infections: findings of a baseline multicentre assessment (CHOICE) in Italy

    by Marzia Lazzerini, Massimo Dagnelut, Paolo Dalena, Idanna Sforzi, Maristella Toniutti, Enrico Felici, Silvia Bressan, Gian Luca Trobia, Stefano Martelossi, Riccardo Lubrano, et al.

    Background Experience is lacking on the implementation of the WHO standards for improving the quality of care (QOC) for children at facility level. We describe the use of 10 prioritised WHO standard-based quality measures to assess provision of care for children with acute respiratory infections (ARI) in Italy. Methods In a multicentre observational study across 11 emergency departments with different characteristics, we collected 10 WHO standard-based quality measures related to case management of children with ARI and no emergency/priority signs. Univariate and multivariate analyses were conducted. Results Data from 3145 children were collected. Major differences in QOC across facilities were observed: documentation of saturation level and respiratory rate varied from 34.3% to 100% and from 10.7% to 62.7%, respectively (pConclusions The use of 10 WHO standard-based measures can help quickly assess QOC for children with ARI. There is an urgent need to invest more in implementation research to identify sustainable and effective interventions to ensure that all children receive high QOC.


  • Open Access

    Implementation of the WHO standards to assess quality of care for children with acute pain in EDs: findings of a multicentre study (CHOICE) in Italy

    by Elia Balestra, Giorgio Cozzi, Idanna Sforzi, Ilaria Liguoro, Enrico Felici, Silvia Fasoli, Silvia Bressan, Marta Minute, Laura Portale, Paolo Dalena, et al.

    Background There is little experience on the use of the WHO Standards for improving the quality of care (QOC) for children. We describe the use of four prioritised WHO Standard-based Quality Measures to assess the provision of care for children with pain in emergency departments (EDs). Methods In a multicentre observational study in 10 EDs with different characteristics in Italy, we collected data on 3355 children accessing the EDs between January 2019 and December 2020. The association between children and facility characteristics and quality measures was analysed through multivariate analyses. Results The proportion of children whose pain was measured was 68.7% (n=2305), with extreme variations across different centres (from 0.0% to 99.8%, pConclusions The use of few WHO Standard-based measures related to pain can help identifying priority gaps in QOC for children and in monitoring it over time. There is a need for more implementation research to establish which are the most sustainable and effective interventions to improve the QOC for acute pain in children.